Page 839 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 817

Carcinoid, 462 Cell division Chemotherapeutic agent (Continued)
sites for, 137 anticancer drugs and, 182 antimicrotubule agent, 194–195
phases of, 36
taxanes, 195
Carcinoma, 63
VetBooks.ir immunohistochemical markers/panels for, Cell kill, ablative techniques for, 169 antitumor antibiotics, 192–193
vinca alkaloids, 195
72t–73t
cryoablation, 169
in spinal cord, 666t Cell mutation, 1 doxorubicin, 192–193
Carcinoma in situ, 169–170 Cell proliferation, immunohistochemistry mitoxantrone, 193
Carcinomatosis, ultrasonography of, 115f and, 71 L-asparaginase, 197
Carcinosarcoma (malignant mixed mammary Cellular gigantism, 131 effects of, 300–301
tumor), 609 Cellular oncogene (c-onc), 41 “extralabel” manner for, 345
Carotenoid, 309 Cellular senescence, 46–47 hydroxyurea, 196–197
Carprofen, 293t–294t Cellularity, 129 pharmacologic activity and
Carrisyn (Acemannan), 24 molecular mechanism for, 69t chemosensitivity of, 184f
Case-control study design, 85–86 Central nervous system tumor, 287t platinums, 196–197
Caspase 8, 39 Central sensitization therapeutic index for, 182–183
Caspase cascade, 53 N-methyl-D-aspartate antagonist and, 295 topoisomerase inhibitors, 195–196
Cationic lipid-DNA complex (CLDC), 237 of pain, 290 epipodophyllotoxins, 196
use of, 237 CEP. see Circulating endothelial progenitor tumor cell resistance to, 185–186
Cavity effusion, 126–127 cell Chemotherapy
tumor metastasis/exfoliating Cerebrospinal fluid analysis cancer, 182–208
into, 145 of intracranial tumors, 662 in canine osteosarcoma, 542–544, 543t
cBMMCs. see Canine bone marrow-derived of spinal cord tumors, 668 gross metastatic disease, 546
mast cells Ceruminous gland, 360 cell specificity of drugs in, 183f
CD4+ T-cell, 233 Ceruminous gland adenocarcinoma, 360–361, clinical trials for, 266–268
adoptive T-cell transfer and, 241–242 360f cutaneous papillomavirus and, 353
CD8+ T-cell, 233 metastatic potential of, 360–361 for digital malignant melanoma, 362
CD44, 54 survival of, 361 for feline sarcomas, 423–424
CDK. see Cyclin-dependent kinase Ceruminous gland adenoma, 360 intent/goals of, 183
CDKs/cyclin complex, 36–37 Ceruminous gland cyst, 360, 360f for intestinal tumor, 467
CEA. see Carcinoembryonic antigen Cervical cancer, HPV and, 26 for intracranial tumors, 662–663
CEC. see Circulating endothelial cell Cesium-137 teletherapy, 630 lymphoma remission and, 190f
Cell CGH. see Comparative genomic hybridization for mast cell tumors, 391
from bladder mass, 129f Chance error, 343 for nasal planum, cancer of, 494
diagnostic quality of, 129 Checkpoint, 37–38 for nasal planum SCC, 357–358
keratinization of, 133 Chemical carcinogenic neutrophil patterns after, 187f
mutation of, 7 cyclophosphamide, 15 for oral melanoma with radiation therapy,
proliferation of, 4–9 environmental tobacco smoke, 14 374–376
from pulmonary/transitional cell observational studies for, 92 for oral tumors, 440
carcinoma, 130f pesticides, herbicides, and insecticides, 15 for orbit and optic nerve tumors, 684
replication of, 46–47 Chemistry, manufacturing, and control for renal lymphoma, 652
Cell adhesion molecule (CAM), 54 (CMC), 345 for soft tissue sarcomas, 416
Cell-cell anchorage, 53 Chemistry profile, for intestinal for spinal cord tumors, 668
Cell-cell contact, 53 tumors, 463 surgery and, 170
Cell cycle Chemodectomas, 137 for urinary bladder tumors, 651
arrest, 37–38 Chemoembolization, of interventional Chemotherapy-induced toxicity
cause of, 39 oncology, 177–179 cumulative/chronic effects of, 187
checkpoint, 37–38 Chemokine, 54 delayed affects of, 187
chemotherapeutic agents and, 183f Chemosensitivity, 184 guidelines for, 187t
control of, 36–37 processes involved in, 184f Cherry eye, 675–676
cyclin-dependent kinases and, 36–37 profiling, 198 Chloracetate esterase, 129
DNA synthesis and, 210 Chemotherapeutic agent Chlorambucil, 191
p53 and, 38f, 41f alkylating agents, 190–192 Chloro-aluminum sulfonated phthalocyanine-
phase of, 36, 37f dacarbazine, 192 based PDT, 169–170
redistribution and reoxygenation nitrogen mustards, 190–191 Cholangiocarcinoma, 455–456, 456f
of, 211 nitrosoureas, 191–192 Chondrocytic tumor, 140–141
Cell death procarbazine, 192 Chondroid matrix, 130
alpha/beta model for, 214f antimetabolites, 193–194 Chondrosarcoma (CSA)
alternative methods of radiation, 211 actinomycin D, 193 in cats, 555
apoptosis and, 39 cytosine arabinoside, 193–194 in dogs, 550–551
autophagy and, 6 5-fluorouracil, 194 fine-needle aspiration of, 140f
evasion of, 46 gemcitabine, 194 in spinal cord, 666t
ionizing radiation and, 209 methotrexate, 193–194 Choroid plexus tumors, 658t